Takeda Pharmaceutical (TAK) Liabilities and Shareholders Equity (2018 - 2026)

Takeda Pharmaceutical's Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $98.9 billion for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 5.91% year-over-year to $98.9 billion in Q1 2026; TTM through Mar 2026 was $394.0 billion, a 0.17% change from a year earlier, with the FY2026 full-year figure at $103.0 billion, up 10.16% from the prior year.
• Liabilities and Shareholders Equity retreated to $98.9 billion in Q1 2026 per TAK's latest filing, from $100.1 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $113.4 billion in Q1 2022 and bottomed at $93.4 billion in Q1 2025.
• The 5-year median for Liabilities and Shareholders Equity is $100.1 billion (2025), against an average of $101.6 billion.
• Across the five-year window, Liabilities and Shareholders Equity retreated 14.43% in 2022 and rose 5.91% in 2026, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $95.6 billion in 2022, then gained by 0.66% to $96.2 billion in 2023, then grew by 3.27% to $99.4 billion in 2024, then grew by 0.76% to $100.1 billion in 2025, then declined by 1.21% to $98.9 billion in 2026.
• Per Business Quant, the three latest TAK Liabilities and Shareholders Equity figures stand at $98.9 billion (Q1 2026), $100.1 billion (Q4 2025), and $98.2 billion (Q3 2025).